Bristol-Myers Squibb Company (BMY) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
BMY's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
BMY Revenue Analysis (2013–2024)
As of March 1, 2026, Bristol-Myers Squibb Company (BMY) generated trailing twelve-month (TTM) revenue of $48.03 billion, reflecting modest growth of +2.8% year-over-year. The most recent quarter (Q3 2025) recorded $12.22 billion in revenue, down 0.4% sequentially.
Looking at the longer-term picture, BMY's 5-year compound annual growth rate (CAGR) stands at +13.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $48.30 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows BMY's business is primarily driven by Eliquis (28%), Opdivo (19%), and Revlimid (12%).
When compared to Healthcare sector peers including LLY (+45.4% YoY), JNJ (+3.7% YoY), and AZN (+8.6% YoY), BMY has underperformed the peer group in terms of revenue growth. Compare BMY vs LLY →
Peer Comparison
Compare BMY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BMYCurrent | $48.0B | +2.8% | +13.1% | 20.0% | |
| LLY | $45.0B | +45.4% | +15.1% | 38.9% | |
| JNJ | $88.8B | +3.7% | +1.6% | 24.9% | |
| AZN | $58.7B | +8.6% | +17.2% | 23.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $48.30B | +7.3% | $27.43B | 56.8% | $9.66B | 20.0% |
| 2023 | $45.01B | -2.5% | $25.36B | 56.3% | $8.47B | 18.8% |
| 2022 | $46.16B | -0.5% | $26.49B | 57.4% | $9.27B | 20.1% |
| 2021 | $46.38B | +9.1% | $26.76B | 57.7% | $9.54B | 20.6% |
| 2020 | $42.52B | +62.6% | $21.70B | 51.0% | $4.49B | 10.6% |
| 2019 | $26.14B | +15.9% | $17.25B | 66.0% | $6.44B | 24.6% |
| 2018 | $22.56B | +8.6% | $16.07B | 71.3% | $6.39B | 28.3% |
| 2017 | $20.78B | +6.9% | $14.96B | 72.0% | $5.24B | 25.2% |
| 2016 | $19.43B | +17.3% | $14.49B | 74.6% | $5.18B | 26.7% |
| 2015 | $16.56B | +4.3% | $12.81B | 77.3% | $3.94B | 23.8% |
See BMY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BMY vs AGIO
See how BMY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BMY's revenue growth accelerating or slowing?
BMY revenue growth slowed to +2.8%, below the 5-year CAGR of +13.1%. TTM revenue is $48.0B. The deceleration marks a shift from historical growth rates.
What is BMY's long-term revenue growth rate?
Bristol-Myers Squibb Company's 5-year revenue CAGR of +13.1% reflects the variable expansion pattern. Current YoY growth of +2.8% is near this long-term average.
How is BMY's revenue distributed by segment?
BMY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.